Please login to the form below

Not currently logged in
Email:
Password:

drug side effects

This page shows the latest drug side effects news and features for those working in and with pharma, biotech and healthcare.

AbbVie enters BCMA race with Teneobio deal

AbbVie enters BCMA race with Teneobio deal

of CAR-Ts, they could emerge as the new standard of care, not having the complicated and expensive manufacturing process with the cell therapies, and also potentially producing fewer side-effects. ... Teneobio’s drug development platform TeneoSeek

Latest news

  • Evenity back on track with FDA panel blessing in osteoporosis Evenity back on track with FDA panel blessing in osteoporosis

    The panel backed the use of the drug in postmenopausal women with osteoporosis at high risk for fracture by 18-1. ... to a much higher risk of cardiovascular side effects than the comparator drug.

  • US says medicine ads should include list prices US says medicine ads should include list prices

    Right now, drug companies are required to disclose the major side effects a drug can have – but not the effect that buying the drug could have on your wallet,” said the ... Azar told the National Academy of Medicine (NAM) that “for too long, drug

  • GSK two-drug trial in untreated HIV raises Gilead rivalry GSK two-drug trial in untreated HIV raises Gilead rivalry

    for HIV – with few side effects and drug interactions. ... That’s one reason the results of the GEMINI trials in untreated HIV are so important to ViiV, giving it two-drug regimens to match Biktarvy across the board.

  • GSK sells eczema and psoriasis drug to Dermavant for £250m GSK sells eczema and psoriasis drug to Dermavant for £250m

    that could provide an alternative to topical and oral steroids, which have side effects. ... In phase II trials the drug had a dose-dependent impact on plaque psoriasis lesions, and it is ready to move to phase III testing.

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    pill, two-drug regimen with the opportunity to reduce the number of drugs needed to treat HIV”. ... At the moment most patients are treated with three-drug regimens, and ViiV says the two-drug regimens can reduce drug exposure and side effects, as well

More from news
Approximately 1 fully matching, plus 99 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Much of this research centred on improving the selectivity of compounds so that they hit the target, M1, without also interacting with similar receptors linked to the intolerable side effects. ... Meanwhile, Karuna Pharmaceuticals has raised $42m to

  • Redirecting your patient strategy Redirecting your patient strategy

    But when people are dealing with their condition for so long, it is important that you understand how they're actually managing it, how they're using the drug.”. ... These new companies have developed novel business models based on sharing the data and

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    IIs are more potent, with fewer side effects and drug interactions and the top reason for prescribing them is their good tolerability profile. ... As patients differ so do their barriers to adherence, whether this be complexity of the dosing regimen,

  • Patients First Patients First

    to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). . ... A natural question to ask is how the benefit finding impacts the final price of a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • What does social media listening actually tell us?

    They have experiences, opinions and ideas which could be used to improve both treatments and practices (such as reports of side effects and effective drug combinations, for example) – and the methods ... The limits and regulations which accompany the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics